vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

vTv Therapeutics (Nasdaq: VTVT) granted 39,500 stock options as material inducements to two non-executive employees under Nasdaq Listing Rule 5635(c)(4).

The options carry a weighted average exercise price of $32.00 per share, vest over four years (25% after one year, then quarterly over 36 months), have a 10-year term, and are governed by the 2026 Inducement Plan and individual option agreements.

News Market Reaction – VTVT

-0.72%

-0.72% Session close to close

In the May 11 session, VTVT declined 0.72%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details routine equity compensation, granting 39,500 stock options at a $32.00 exe...

Analysis

This announcement details routine equity compensation, granting 39,500 stock options at a $32.00 exercise price that vest over four years with a 10-year term as inducements to new employees. It fits a recent pattern of option-based awards under the 2026 Inducement Plan. Against a backdrop of an effective S-3 shelf and prior going-concern language, investors may focus more on future financing steps and clinical milestones than on this modest, time-vested grant.

Key Figures

Inducement options granted: 39,500 options Exercise price: $32.00 per share Vesting schedule: 4 years (25% at 1 year, then quarterly) +1 more

4 metrics

Inducement options granted 39,500 options Granted to two non-executive employees as inducements

Exercise price $32.00 per share Weighted average exercise price of new options

Vesting schedule 4 years (25% at 1 year, then quarterly) Time-based vesting for each option award

Option term 10 years Contractual life of the inducement stock options

Historical Context

5 past events · Latest: Apr 07 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 07	Inducement option grant	Neutral	+0.6%	Grant of 4,000 stock options to a non-executive employee under inducement plan.
Mar 16	Conference participation	Positive	+7.4%	Announcement of fireside chat and 1x1 meetings at the 38th ROTH Conference.
Mar 10	Earnings and update	Neutral	+0.2%	Q4 and 2025 results plus cash position and Phase 3 CATT1 enrollment outlook.
Feb 13	Investor conferences	Neutral	-7.2%	Participation in Oppenheimer and TD Cowen healthcare conferences with webcasts.
Feb 02	License amendment	Positive	+8.2%	Expanded Newsoara license for HPP737 with upfront, milestones, and royalties.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news, including licensing and conference updates, has generally seen aligned price reactions, with only one notable divergence on neutral conference participation news.

Recent Company History

Over the last few months, VTVT has reported a mix of corporate developments: option inducement grants (Apr 7, 2026), multiple conference appearances, 2025 financial results with clinical updates, and a materially positive amended license for HPP737 with milestones and royalties (Feb 2, 2026). Price reactions to these items were mostly modest and directionally aligned with the underlying news. Today’s further inducement grants continue a pattern of using equity-based compensation within the 2026 Inducement Plan framework.

Key Terms

nasdaq listing rule 5635(c)(4), stock options, exercise price

3 terms

nasdaq listing rule 5635(c)(4) regulatory

"as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

stock options financial

"it granted 39,500 stock options to purchase shares of common stock to two non-executive"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"The stock options that were granted have a weighted average exercise price of $32.00 per"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HIGH POINT, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 39,500 stock options to purchase shares of common stock to two non-executive employees as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options that were granted have a weighted average exercise price of $32.00 per share. Each option award will vest over a 4-year period, with 25% of the shares underlying the option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting quarterly over the following 36 months, subject to continued employment with vTv on such vesting dates. The options have a term of 10 years and are subject to the terms and conditions of the 2026 Inducement Plan and the stock option agreement covering the grant.

About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a US Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.

About Cadisegliatin
Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the US as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin acted selectively on the liver and increased the activity of glucokinase independently from insulin. These studies support clinical investigation of whether cadisegliatin can improve glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).

Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.

Investor Contact
John Fraunces
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com

Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com

FAQ

How many options did vTv Therapeutics (VTVT) grant on May 8, 2026?

vTv granted 39,500 stock options to two non-executive employees as inducements to employment. According to vTv, the awards were made under Nasdaq Listing Rule 5635(c)(4) and are subject to the 2026 Inducement Plan and option agreements.

What is the exercise price and term of the VTVT inducement stock options?

The options have a weighted average exercise price of $32.00 per share and a 10-year contractual term. According to vTv, option rights are governed by the 2026 Inducement Plan and the applicable stock option agreements.

What is the vesting schedule for the VTVT options granted May 8, 2026?

Each option award vests over four years: 25% vests on the one-year anniversary, then the remainder vests quarterly over the next 36 months. According to vTv, continued employment on each vesting date is required for vesting.

Who received the inducement grants from vTv Therapeutics (VTVT)?

The grants were issued to two non-executive employees as material inducements to employment. According to vTv, the awards were made under Nasdaq Listing Rule 5635(c)(4) and are subject to plan and agreement terms.

Why did vTv Therapeutics use Nasdaq Listing Rule 5635(c)(4) for the grants?

vTv used Nasdaq Listing Rule 5635(c)(4) to classify the awards as inducement grants tied to new employment, permitting issuance outside prior shareholder approval. According to vTv, this rule authorizes material inducements granted to new employees.